Corporate principles of Interprotein is "The contribution to health and welfare of humankind by supplying medicines to patients in all over the world, and Interprotein is engaging business with a management vision of "The discovery of innovative medicines that are widely used and not burdening patients with heavy costs".

Programs of Interprotein are divided into two areas, one of which is "Drug discovery" and the other is "Improvement of production yield of recombinant proteins" as follows:

"Drug discovery programs" consist of research & development of small molecule protein-protein interaction (PPI) inhibitors based on a unique in silico molecular design concept, which is a platform technology of Interprotein, and zinc chelator for regulating various kinds of allergic responses.

"Improvement of production yield of recombinant proteins" is based on a technology that increase production amounts of recombinant proteins such as antibody medicines in response to mild cold stimulation.

R&D portfolio of Interprotein is summarized as following figure: